Management strategies in SSRI-associated sexual dysfunction in women at midlife

Climacteric

Volumn 15, Issue 4, 2012, Pages 306-316

  Fooladi, E ^a   Bell, R J ^a   Davis, S R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

DEPRESSION; MANAGEMENT STRATEGIES; MIDLIFE; SEXUAL DYSFUNCTION; SSRIs; WOMEN

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FOLLITROPIN; GINKGO BILOBA EXTRACT; GRANISETRON; LUTEINIZING HORMONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2C AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE;

CLINICAL FEATURE; CONSULTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; FEMALE SEXUAL DYSFUNCTION; FLUSHING; HAMILTON SCALE; HEADACHE; HUMAN; HUMAN RELATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIBIDO DISORDER; LIFE; MAJOR DEPRESSION; MENOPAUSE AND CLIMACTERIUM; MIDLIFE; MOOD; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF ESTEEM; SEX RATIO; SEXUAL BEHAVIOR; SIDE EFFECT; SOCIAL PSYCHOLOGY; TREATMENT CONTRAINDICATION; WOMEN'S HEALTH;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84863579454     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.658461     Document Type: Review

References (105)

1. Kessler RC, McGonagle KA, Nelson CB, Hughes M, Swartz M, Blazer DG. Sex and depression in the National Comorbidity Survey. II. Cohort effects. J Affect Disorders 1994;30:15-26
2. Kessler RC, Berglund P, Demler O, e t a l. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
3. Weissman MM, Olfson M. Depression in women: Implications for health care research Science 1995;269:799-801
4. McKnight-Eily LR, Presley-Cantrell L, Elam-Evans LD, Chapman DP, Kaslow NJ, Perry GS. Prevalence and correlates of current depressive symptomatology and lifetime diagnosis of depression in black women. Women' Health Issues 2009;19:243-52
5. Weissman MM, Bland RC, Canino GJ, e t al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9
6. Kessler RC, McGonagle KA, Swartz M, Blazer DB, Nelson CB. Sex and depression in the National Comorbidity Survey. I. Lifetime prevalence,chronicity and recurrence. J Affect Disorders 1993;29:85-96
7. Laumann E, Paik A, Rosen RC. Sexual dysfunction in the United States:prevalence and predictors. JAMA 1999;281:537-44
8. Basson R. Sexual sequelae of general medical disorders. Lancet 2007;369:409-24
9. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56:201-8
10. Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressantinduced sexual dysfunction in two European countries: A cross-sectional patient survey. J Clin Psychiatry 2006;67: 204-10
11. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21
12. W erneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006;114:384-97
13. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: Review. Aust NZ J Psychiatry 2009;43: 795-808
14. Williams DR, Gonzalez HM, Neighbors H, e t a l. Prevalence and distribution of major depressive disorder in African Americans, Caribbean Blacks, and Non-Hispanic whites: Results from the National Survey of American life. Arch Gen Psychiatry 2007;64:305-15
15. Strine TW, Koroenke K, Dhingra S, et a l . The association between depression health-related quality of life, social support, life satisfaction, and disability in community-dwelling US adults. J Nervous Mental Dis 2008;197:61-4
16. American Psychiatric Association. D iagnostic and Statistical Manual of Mental Disorder. Washington, DC: AMERICAN Psychiatric Association, 2000
17. Byles J, Loxton D, Berecki J, e t al. Use and costs of medications and other health care resources: FINDINGS from the Australian Longitudinal Study on Women' Health. University of Newcastle and the University of Queensland: WOMENS Health Australia, 2008
18. Murrell SA, Himmelfarb S, Wright K. Prevalence of depression and its correlates in older adults. Am J Epidemiol 1983;117: 173-85
19. Ustun T, Ayuso Mateos J, Chatterji S, Matthers C, Murracy C. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92
20. Murray J, Lopez A, eds. T he Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Summary . Boston: HARVARD School of Public Health, 1996
21. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007;21:374-83
22. Judd L. Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol 1995;10(Suppl 4):5-10
23. Cuijpers P, Smit F. Subthreshold depression as a risk indicator for major depressive disorder: A systematic review of prospective studies. Acta Psychiatr Scand 2004;109:325-31
24. Patten SB, Wang JL, Williams JVA, e t a l. Descriptive epidemiology of major depression in Canada. Can J Psychiatry 2006;51: 84-90
25. Noble RE. Depression in women. M etabolism 2005;54(Suppl 1):49-52
26. Holsboer F, Lauer CJ, Schreiber W, Krieg JC. Altered hypothalamic- pituitary-Adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;62:340-7
27. Yehuda R, Golier JA, Kaufman S. Circadian rhythm of salivary cortisol in Holocaust survivors with and without PTSD. Am J Psychiatry 2005;162:998-1000
28. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry 1976;33:1051-8
29. Stetler C, Miller GE. Depression and hypothalamic-pituitaryadrenal activation: A quantitative summary of four decades of research. Psychosom Med 2011;73:114-26
30. Lehnert H, Schulz C, Dieterich K. Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: The role of the locus coeruleus. Neurochem Res 1998;23:1039-52
31. Florian H. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501
32. Accortt EE, Freeman MP, Allen JJ. Women and major depressive disorder: Clinical perspectives on causal pathways. J Women' Health 2008;17:1583-90
33. Alexander JL, Dennerstein L, Fugate Woods N, et al . Neurobehavioral impact of menopause on mood. Exp Rev Neurotherapeutics 2007;7(11 Suppl):S81 - 91
34. Clayton AH, Ninan PT. Depression or menopause Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry 2010;12:e1 - 13
35. Freeman EW, Sammel MD, Lin H, et a l. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110:230-40
36. Freeman EW. Associations of depression with the transition to menopause. Menopause 2010;17:823-7
37. Dennerstein L, Soares CL. The unique challenges of managing depression in mid-life women. World Psychiatry 2008;7: 137-42
38. Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its infl uence on reproductive endocrine and menstrual cycle markers associated with perimenopause: THE Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003;60: 29-36
39. Rasgon N, Shelton S, Halbreich U. Perimenopausal mental disorders:epidemiology and phenomenology. CNS Spectrums 2005;10:471-8
40. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-82
41. Gallicchio L, Schilling C, Miller SR, Zacur H, Flaws JA. Correlates of depressive symptoms among women undergoing the menopausal transition. J Psychosom Res 2007;63:263-8
42. Woods NF, Smith-DiJulio K, Percival DB, Tao EY, Mariella A, Mitchell ES. Depressed mood during the menopausal transition and early postmenopause: Observations from the Seattle Midlife Women' Health Study. Menopause 2008;15:223-32
43. Woods NF, Smith-Dijulio K, Percival DB, Tao EY, Taylor HJ, Mitchell ES. Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: Observations from the Seattle Midlife Women' Health Study. J Womens Health (Larchmt) 2007;16:667-77
44. Santoro N, Torrens J, Crawford S, et al . Correlates of circulating androgens in mid-life women: The Study of Women' Health Across the Nation. J Clin Endocrinol Metab 2005;90: 4836-4845
45. Roberts CGP, Ladenson PW. Hypothyroidism. L ancet 2004;363:793-803
46. Fountoulakis KN, Kantartzis S, Siamouli M, e t al . Peripheral thyroid dysfunction in depression. World J Biol Psychiatry 2006;7:131-7
47. Rapkin A, Mikacich J, Moatakef-Imani B, Rasgon N. The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders. Curr Psychiatry Rep 2002;4:419-28
48. Schmidt P, Rubinow D. Menopause-related affective disorders: A justifi cation for further study. Am J Psychiatry 1991;148: 844-52
49. American Psychiatric Association. D iagnostic and Statistical Manual of Mental Disorders . Washington, DC: AMERICAN Psychiatric Press, 1994
50. Stahl SM. The psychopharmacology of sex. Neurotransmitters and the 3 phases of the human sexual response. J Clin Psychiatry 2001;62:80-1
51. Johannes CB, Clayton AH, Odom DM, et a l. Distressing sexual problems in United States women revised: Prevalence after accounting for depression. J Clin Psychaitry 2009;70: 1698-1706
52. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: Conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev 2009;29:573-85
53. Bartlik B, Kocsis J, Legere R, Villaluz J, Kossoy A, Gelenburg A. Sexual dysfunction secondary to depressive disorders. J Gend Specif Med 1999;2:52-60
54. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008;112:970-8
55. Dennerstein L, Guthrie JR, Hayes RD, DeRogatis LR, Lehert P. Sexual Function, dysfunction, and sexual distress in a prospective, population-based sample of mid-Aged, Australian-born women. J Sex Med 2008;5:2291-9
56. Martin-Merino E, Ruigomez A, Johansson S, Wallander MA, Garcia-Rodriguez LA. Study of a cohort of patients newly diagnosed with depression in general practice: Prevalence, incidence, comorbidity, and treatment patterns. Prim Care Companion J Clin Psychiatry 2010;12:PCC 08m00764
57. Thacker HL. Assessing risks and benefi ts of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. J Womens Health (Larchmt) 2011;20: 1007-1016
58. Sjoerdsma T, Palfregman A. A history of serotonin. Ann NY Acad Sci 1990;600:2-9
59. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:85-102
60. Laumann EO, Glasser DB, Neves RCS, Moreira ED Jr. A population-based survey of sexual activity, sexual problems and associated help-seeking behavior patterns in mature adults in the United States of America. Int J Impot Res 2009;21:171-8.
61. Stahl SM. Basic psychopharmacology of anti-depressants. 1. Clin Psychiatry 1998;59(Suppl 4):5-14
62. Damsa C, Bumb A, Bianchi-Demicheli F. Dopamine dependent side-effects of selective serotonin reuptake inhibitors: A clinical review. J Clin Psychiatry 2004;65:1064-8
63. Rosen R, Lane R, Menza M. Effects of SSRIs on sexual function: A critical review. J Clin Psychopharmacol 1999;19:67-85
64. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRIinduced sexual dysfunction: Fl uoxetine, paroxetine, sertraline, and fl uvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94
65. Davison SL, Bell RJ, LaChina M, Holden SL, Davis SR. The relationship between self-reported sexual satisfaction and general well-being in women. J Sex Med 2009;6:2690-7
66. Davis S, Katz J, Jackson JL. Sexual desire discrepancies: Effects on sexual and relationship satisfaction in heterosexual dating couples. Arch Sex Behav 1999;28:553-67
67. Santtila P, Wager I, Witting K, et al. Discrepancies between sexual desire and sexual activity: Gender differences and associations with relationship satisfaction. J Sex Marital Ther 2008;34:29-42
68. Witting K, Santtila P, Varjonen M, et a l. Female sexual dysfunction, sexual distress, and compatibility with partner. J Sex Med 2008;5:2587-99
69. Brezsnyak M, Whisman MA. Sexual desire and relationship functioning: The effects of marital satisfaction and power. J Sex Marital Ther 2004;30:199-217
70. Manderson L. The social and cultural context of sexual function among middle-Aged women. Menopause 2005;12:361-2
71. Nijs P. Counselling of the climacteric woman: Diagnostic diffi -culties and therapeutic possibilities. Eur J Obstet Gynecol Reprod Biol 1998;81:273-6
72. Ferguson JM, Shrivastava RK, Stahl SM, e t a l. Reemergence of sexual dysfunction in patients with major depressive disorder: Double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 2001;62:24-9
73. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant effi cacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33
74. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65:62-7
75. Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268-71
76. Michelson D, Kociban K, Tamura R, Morrison MF. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-Associated female sexual dysfunction: A randomized, placebo controlled trial. J Psychiatr Res 2002;36:147-52
77. Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol 2004;19:545-8
78. Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002;17:279-84
79. Jespersen S, Berk M, Van Wyk C, e t a l. A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use. Int Clin Psychopharmacol 2004;19:161-4
80. Meston CM. A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction. J Sex Marital Ther 2004;30:57-68
81. Nelson EB, Shah VN, Welge JA, Keck PE Jr. A placebocontrolled, crossover trial of granisetron in SRI-induced sexual dysfunction. J Clin Psychiatry 2001;62:469-73
82. Salonia A, Rigatti P, Montorsi F. Sildenafi l in erectile dysfunction: A critical review. Curr Med Res Opin 2003;19:241-62
83. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and effi cacy of sildenafi l citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. J Urol 2003;170:2333-8
84. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafi l treatment of women with antidepressantassociated sexual dysfunction: A randomized controlled trial. JAMA 2008;300:395-404
85. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafi l citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: A randomised controlled trial. BJOG 2003;110:1014-24
86. Davison S, Bell R, Donath S, Montalto J, Davis S. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53
87. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-8
88. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-6
89. Rivera-Woll LM, Papalia M, Davis SR, Burger HG. Androgen insuffi ciency in women: Diagnostic and therapeutic implications. Hum Reprod Update 2004;10:421-32
90. Uwe DR. The impact of testosterone imbalance on depression and Women' health. Maturitas 2002;41(Suppl 1):25-46
91. Braunstein GD, Sundwall DA, Katz M, et a l. Safety and effi cacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9
92. Buster JE, Kingsberg SA, Aguirre O, e t al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-52
93. Simon J, Braunstein G, Nachtigall L, e t al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33
94. Shifren J, Davis SR, Moreau M, e t a l. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 study. Menopause 2006;13:770-9
95. Davis SR, van der Mooren MJ, van Lunsen RHW, e t al. The effi cacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-96
96. Davis SR, Moreau M, Kroll R, e t al. Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl J Med 2008;359:2005-17
97. Goldstat R, Briganti E, Tran J, Wolfe R, Davis S. Transdermal testosterone improves mood, well being and sexual function in premenopausal women. Menopause 2003;10:390-8
98. Davis SR, Papalia MA, Norman RJ, e t al. Safety and effi cacy of a testosterone metered-dose transdermal spray for treatment of decreased sexual satisfaction in premenopausal women: A placebo-controlled randomized, dose-ranging study. Ann Intern Med 2008;148:569-77
99. Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function and wellbeing in postmenopausal women treated with testosterone: A randomized placebo controlled trial. Menopause 2006;13:37-45
100. Shifren JL, Braunstein G, Simon J, et a l. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8
101. Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162-70
102. Taylor MJ, Rudkin L, Hawton K. Strategies for managing anti-depressant-induced sexual dysfunction: Systematic review of randomised controlled trials. J Affect Disord 2005;88: 241-54
103. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005;66: 844-848
104. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: A randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001;158:805-7
105. Michelson D, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000;157:239-43